MPE data support a dual role for TP53 alterations in cell-cycle deregulation and cell autonomy in relation to the energy balance [240], while FASN-negative and FASN-positive tumours have been reported to be associated with a significantly different CRC risk [241]. This evidence concerns the gene TP53 and neoplasm.